What moved MOLN.SW stock pre-market today?

MOLN.SW stock rose pre-market to **CHF 3.94** on **8.84%** gains and elevated volume. The move reflects technical buying and positioning ahead of a March earnings/clinical update window.

What is Meyka AI's view on MOLN.SW stock?

Meyka AI rates MOLN.SW **64.33/100 (B) – HOLD**. The grade balances strong cash per share and technicals against negative EPS, limited revenue and trial risks.

What price target and forecast exist for MOLN.SW stock?

Meyka AI's forecast model projects **CHF 2.61** in 12 months, implying **-33.67%** vs **CHF 3.94**. Model targets: base **CHF 4.50** (+14.21%) and conservative **CHF 2.60** (-34.01%).

Which risks should investors watch for MOLN.SW stock?

Key risks include clinical trial setbacks, partner delays, further cash burn, and dilution. Sector cyclicality and biotech news flow can amplify volatility for MOLN.SW stock.

CH Stocks

MOLN.SW (SIX) Molecular Partners CHF3.94 pre-market Feb 2026: watch March earnings

ByHuzaifa Zahoor February 20, 2026February 20, 2026

We see MOLN.SW stock trading at CHF 3.94 pre-market after an intraday gain of 8.84% and volume of 26,819 shares. The move puts Molecular Partners (SIX) back near its 50-day average of CHF 3.36. We track the jump as a high-volume mover ahead of a scheduled earnings window and near-term clinical and collaboration catalysts. Meyka AI, an AI-powered market analysis platform, flags the trade as volume-driven and tied to near-term news flow and technical strength.